each group, there was no significant difference in the degree of lipid abnormalities between apo e2 carrier Objectives. Apolipoprotein E (apo E) is known to play an important role in lipoprotein metabolism through (e2/2, e2/3 genotypes), e3 carrier (e3/3 genotype) and e4 carrier (e3/4, e4/4 genotype). its ability to bind to the receptors as a ligand. Three different apo E alleles (e2, e3 and e4) produce six apo Conclusion. Apo e2 allele and e2 carrier frequencies were significantly higher in macroalbuminuria group. E genotypes (e2/2, e2/3, e2/4, e3/3, e3/4 and e4/4). The objective of this study was to investigate an association These results suggest that e2 allele may be associated with the development of clinical albuminuria in Korean between apo E gene polymorphism and macroalbuminuria in 167 Korean patients with non-insulin dependent patients with NIDDM. diabetes mellitus (NIDDM ). Methods. The patients in the macroalbuminuria group Key words: apolipoprotein E; polymorphism; macroalbuminuria; normoalbuminuria (n=74) represent those in whom 24 h urinary albumin excretion was above 300 mg. The patients in the normoalbuminuria group (n=93) represent those in whom 24 h urinary albumin excretion was below 30 mg and
Introduction
serum creatinine levels were less than 1.2 mg/dl. The duration of diabetes in all patients was at least 8 years.
Results. There were no significant differences in terms Diabetic nephropathy is a major cause of morbidity and of age, sex, body mass index, HbA 1c
, total cholesterol, premature mortality in patients with non-insulin dependtriglyceride, HDL-cholesterol and LDL-cholesterol ent diabetes mellitus (NIDDM ). The pathophysiological between the two groups. In the macroalbuminuria mechanism for the development and progression of diagroup, the distribution of apo E genotypes revealed betic nephropathy is not well known, but several factors e2/2 2 (2.7%), e2/3 14 (18.9%), e2/4 0 (0%), e3/3 47 have been linked to this. Among these factors, it has been (63.5%), e3/4 11 (14.9%) and e4/4 0 (0%). In the proposed that lipid abnormalities possibly contribute to normoalbuminuria group, the distribution of apo E the development and progression of the kidney diseases genotypes revealed e2/2 0 (0%), e2/3 7 (7.5%), e2/4 1 including diabetic nephropathy [1] [2] [3] [4] [5] [6] . The human apo-(1.1%), e3/3 72 (77.4%), e3/4 12 (12.9%) and e4/4 1 lipoprotein E (apo E) is composed of 299 amino acids (1.1%). There was no significant difference in the and is a polymorphic glycoprotein [7] . Recently, apo E distribution of apo E genotypes between the two alleles have been reported to be important genetic groups. However, there was a significant difference in markers for dyslipidaemia associated with coronary the allele frequencies, e2 frequency was significantly artery disease [8] , and there appear to be similar pathohigher in macroalbuminuria group compared to nor-physiological mechanisms in the development of glommoalbuminuria group (12.2% vs 4.3%, P<0.05). Also, erulosclerosis and atherosclerosis [4, 9] . It is possible that we compared apo E carrier frequencies between the the development of diabetic nephropathy in patients with two groups. e2 carrier frequency was significantly NIDDM is associated with apo E polymorphism. Apo higher in macroalbuminuria group compared to nor-E is not only a major protein of very low density lipopromoalbuminuria group (21.6% vs 7.6%, P<0.05). In tein ( VLDL), but also present in almost all kinds of lipoproteins including chylomicron, chylomicron rem- Apo E gene is located on chromosome 19 and its beta-blockers, alpha-blockers and combinations of the above genetic polymorphism is well known [12] . It has three drugs. Forty-eight out of 74 patients in macroalbuminuria common alleles coding for three isoforms of apo E group and 41 out of 93 patients in normoalbuminuria group protein, e2, e3 and e4 at a single genetic locus producing were on antihypertensive therapy. In macroalbuminuria group, the apo E isoproteins, apo E2, E3 and E4. Apo E3, 21 out of 48 (43.8%) patients used ACE inhibitors. In normothe native form (wild type), is the most common apo albuminuria group, 9 out of 41 (22.0%) patients used ACE inhibitors which was low compared to macroalbuminuria E isoproteins. Apo E2 is commonly caused by a change group. We also used lovastatin and gemfibrosil for the purposes of residue 158 from Arg to Cys (Arg 158 Cys). In of lowering serum cholesterol and triglyceride. In macroalbumiapo E4, Cys is substituted by Arg at 112th amino acid nuria group, 22 out of 74 (29.7%) patients used gemfibrosil and (Cys 112 Arg). According to the genetic models of 7 out of 74 (9.5%) patients used lovastatin. In normoalbuminuthe three alleles, six apo E genotypes (e2/2,e2/3,e3/3, ria group, 10 out of 93(10.8%) and 3 out of 93 (3.2%) patients e2/4,e3/4, e4/4) and six phenotypes ( E2/2, E2/3, E3/3, used gemfibrosil and lovastatin, respectively. E2/4, E3/4, E4/4) are recognized by isoelectric focusing [10] . This polymorphism of apo E gene is known to influence the lipid metabolism because the product of Methods e2 and e4 alleles has different characteristics from that of e3 allele. Apo e2 exhibits reduced binding to the Specimen collection. After 12 h of overnight fast, 5 ml of EDTA-anti coagulated blood samples were drawn from the receptors, and contributes to the accumulation of patients, and were centrifuged within 4 h. Buffy coat layers remnant particles in plasma derived from the partial were refrigerated for DNA extraction at −20°C. 
Subjects and Methods
in whom at least two of the three collections showed elevated levels (>300 mg/24 h). We took the mean of the last two measurements of urinary albumin excretion. Because of Subjects potential antiproteinuric effect of antihypertensive therapy, we temporarily discontinued antihypertensive drugs 2 days One hundred and sixty seven NIDDM patients were recruited from renal and endocrine units of the Department of Internal before urine samples were collected.
Determination of apolipoprotein E genotypes. ApoE genotypMedicine, Yongdong Severance Hospital, Yonsei University, from March 1994 to July 1997. Patients were composed of ing was performed with PCR-restriction fragment length polymorphism as Hixon and Vernier [20] with slight modi-74 diabetics with macroalbuminuria and 93 normoalbuminuric patients. They were all Koreans. The macroalbuminuric fication as follows. The oligonucleotide sequences were:
F4: 5∞-ACA GAA TTC GCC CCG GCC TGG TAC AC-3∞ diabetic group (n=74) represents those in whom 24 h urinary albumin excretion was above 300 mg. The normoalbuminuria F6: 5∞-TAA GCT TGG CAC GGC TGT CCA AGG A-3∞ to amplify the specific fragment apoE genomic DNA in group (n=93) represents those in whom 24 h urinary albumin excretion was below 30 mg and normal renal function (serum preparation for subsequent digestion with restriction endonuclease. Final concentration of each constituent in 50 ml creatinine ∏1.2 mg/dl ). The duration of diabetes mellitus in all patients was at least 8 years.
reaction was as follows: dNTP (Pharmacia Biotech), 0.2 mM; each upstream (F4) and downstream (F6) oligonucleotide We excluded patients with microalbuminuria in this study because in NIDDM, microalbuminuria may be present more primer, 0.2 mM; genomic DNA, 100 ng (500-200 ng); MgCl 2 , 2 mM; KCl, 50 mM; Tris-HCl, pH 8.3, 10 mM. We denatured frequently for reasons other than diabetic nephropathy compared with macroalbuminuria. Familial hyperlipidaemia, DNA first at 95°C for 5 min and added 1.5 Unit of Taq polymerase (Perkin Elmer) to each sample at 72°C. We liver disease, thyroid disease and non-diabetic renal disease were excluded.
amplified DNA as follows: 95°C for 40 s, 60°C for 30 s, 72°C for 30 s for 35 cycles, and final extension time 10 min at A diagnosis of hypertension was made if the patient had two 72°C. We checked the 244 bp PCR product and digested ween the two groups. In the macroalbuminuric diabetic with HhaI (Gibco BRL, Life Technologies, Gaithersburg, group, the level of blood urea nitrogen was MD, USA) with concentration of 0.5 U/ml for 3 h at 37°C. 45.8±23.7 mg/dl, and in the normoalbuminuric diaWe separated the digested PCR product at 4% MetaPhor betic group 17.3±7.7 mg/dl (P<0.05). The level of TM agarose (FMC BioProduct, ME, USA) and 0.5 mg/l serum creatinine was 4.7±3.6 mg/dl in the macroalbuethidium bromide gel and determined the apoE genotyping. minuric diabetic group, and 1.0±0. 2 Figure 1 ) There were no significant differences in age, sex, body mass index, duration of diabetes, total cholesterol, In the macroalbuminuric diabetic group, apo E genotypes revealed 2 (2.7%) patients with e2/2, 14 (18.9%) HDL-cholesterol, LDL-cholesterol, and HbA 1C bet- Values are mean±SD. *P<0.05, statistically significant differences between the two groups. (Table 4) allele and carrier frequencies between the two groups were significantly different.
In the macroalbuminuric diabetic group, the mean levels of total cholesterol were 213.1±48.1 mg/dl in apo e2 carrier, 199.9±72.6 mg/dl in apo e3 carrier, with e2/3, 0 (0%) with e2/4, 47 (63.5%) with e3/3, 11 (14.9%) with e3/4 and 0 (0%) with e4/4. In the normoal-and 210.4±89.8 mg/dl in apo e4 carrier (P>0.05).
In the normoalbuminuric group, the mean levels of buminuric diabetic group, apo E genotypes revealed 0 (0%) patients with e2/2, 7 (7.5%) with e2/3, 1 (1.1%) total cholesterol were 194.6±71.5 mg/dl in apo e2 carrier, 195.1±41.3 mg/dl in apo e3 carrier, and with e2/4, 72 (77.4%) with e3/3, 12 (12.9%) with e3/4 and 1 (1.1%) with e4/4. There was no significant 225.8±56.3 mg/dl in apo e4 carrier (P>0.05). The mean levels of triglyceride, HDL-cholesterol, and difference between the two groups in the distribution of apo E genotypes. However, the frequency of apo e2 LDL-cholesterol are shown in Table 4 . There were no significant differences between apo e2 carrier (e2/2, e2/3 allele was significantly higher in the macroalbuminuric diabetic group compared to the normoalbuminuric genotypes), e3 carrier (e3/3 genotype) and e4 carrier (e3/4, e4/4 genotypes) in each group in the levels of group (12.2% vs 4.3%, P<0.05). Also, patients were grouped according to their apo e allele carrier status cholesterol, triglyceride, HDL-cholesterol and LDLcholesterol (P>0.05). as one of the following: e2 carrier (e2/2, e2/3 geno- with normoalbuminuria but e2 allele frequency was significantly higher in diabetic patients with macroalbuminuria. Distribution of apo E allele frequency of our normoalbuminuric diabetic group was similar to Japanese population. Recent studies have reported inconsistent associations between apo E polymorphism and diabetic nephropathy in various populations [13] [14] [15] [16] [17] [18] . Ukkola et al. [13] showed that apo E2 phenotype including apo E2/3 and E2/4 protected from macroand micro-vascular complications in NIDDM. In contrast, apo E4/4 and E4/3 tended to increase the risk for macroangiopathy. The lower prevalence of macroangi- Fig. 1 . Distribution of apo E allele and carrier frequencies between opathy in patients with apo E2 phenotype was associated the two groups. (*P<0.05).
with lower plasma total and LDL cholesterol levels. They concluded that apo E phenotype modulated the Discussion risk for diabetic complications in patients with NIDDM. Boize et al. [14] in Europe also reported that the prevalIn this study, serum lipid profiles were not significantly ence of nephropathy in NIDDM was significantly different between macroalbuminuric diabetic and nor-reduced in e2 allele carrier. They supported evidence for moalbuminuric groups. Onuma et al. [16 ] reported the role of LDL in the development of diabetic nephrothat serum cholesterol and triglyceride levels were pathy as in atherosclerosis. Diabetics and non-diabetic higher in patients with proteinuria than in those with subjects carrying the E2 allele had lower total and LDL normoalbuminuria. Mulec et al. [1] also reported that cholesterol concentrations. In subsequent years, Horita in type I diabetic patients with nephropathy, patients et al. [15] and Eto et al. [16 ] from Japan reported that with low serum cholesterol concentration exhibited the e2 allele frequency was significantly higher in diabetic considerably slower decline in kidney function than patients with nephropathy and renal failure, which sugthose with high serum cholesterol concentration, sug-gested that apo e2 would be associated with nephropathy gesting that hypercholesterolaemia could contribute to and renal insufficiency in NIDDM. They suggested that more rapid progression of renal disease in patients increased plasma levels of remnants and triglyceride-rich with diabetic nephropathy. Recently, the significance lipoproteins which were associated with apo E2 in of hypercholesterolaemia for progressive renal damage NIDDM contributed to the renal damage in NIDDM, has been established in experimental models of kidney although there was no evidence to support a direct link disease. Specially, hypercholesterolaemia can markedly between remnants and renal damage. There were several aggravate nephron injury in the presence of other case reports of so called lipoprotein glomerulopathy in glomerular diseases [21, 22] . Lipid-lowering therapies recent years [23, 24] . This entity is characterized by the can prevent or attenuate this injury. However, very presence of apo E2, type III hyperlipoproteinaemia-like little is known about the long-term effects of elevations lipoprotein profiles and proteinuria. These reports supof serum cholesterol or other lipids on kidney disease ported the possibility that increased remnants in plasma in man. As previously mentioned, total cholesterol and associated with apo E2 may contribute to renal damage triglyceirde levels are higher in patients with NIDDM but a direct link between apo E2 and diabetic nephroand nephropathy but our study revealed no significant pathy remains speculative. Our study showed the same differences. This is probably due to the effect of treatfinding as Horita et al. and Eto et al. as far as the ment at the time of study (we used lovastatin and relationship between apo E2 and macroalbuminuria. gemfibrosil for the purposes of lowering serum cholesOnuma et al. [17] investigated the relationship between terol and triglyceride, respectively).
apo E polymorphism and diabetic nephropathy in In this study, the distribution of apo E genotypes in patients with macroalbuminuria was similar to patients Caucacian patients with IDDM. They did not see any odds ratio by failure time anlaysis using cox-proportional [3445] [3446] [3447] [3448] [3449] hazard model and revealed that the carriage of apo e2 13. Ukkola O, Kervinen K, Salmela PI, Dickhoff KV, Laakso M, Kesaniemi YA. Apolipoprotein E phenotype is related to macroallele has a 3.466 times higher chance to macroalbuminu- 
